Literature DB >> 21691113

Genetic factors in the pathogenesis of cholangiocarcinoma.

Christopher A Wadsworth1, Peter H Dixon, Jason H Wong, Michael H Chapman, Siobhan C McKay, Amar Sharif, Duncan R Spalding, Stephen P Pereira, Howard C Thomas, Simon D Taylor-Robinson, John Whittaker, Catherine Williamson, Shahid A Khan.   

Abstract

BACKGROUND: Cholangiocarcinoma (CC) is increasing in incidence, but its pathogenesis remains poorly understood. Chronic inflammation of the bile duct and cholestasis are major risk factors, but most cases in the West are sporadic. Genetic polymorphisms in biliary transporter proteins have been implicated in benign biliary disease and, in the case of progressive familial cholestasis, have been associated with childhood onset of CC. In the current study, five biologically plausible candidate genes were investigated: ABCB11 (BSEP), ABCB4 (MDR3), ABCC2 (MRP2), ATP8B1 (FIC1) and NR1H4 (FXR).
METHODS: DNA was collected from 172 Caucasian individuals with confirmed CC. A control cohort of healthy Caucasians was formed. Seventy-three SNPs were selected using the HapMap database to capture genetic variation around the five candidate loci. Genotyping was undertaken with a competitive PCR-based system. Confirmation of Hardy-Weinberg equilibrium and Cochran-Armitage trend testing were performed using PLINK. Haplotype frequencies were compared using haplo.stats.
RESULTS: All 73 SNPs were in Hardy-Weinberg equilibrium. Four SNPs in ABCB11 were associated with altered susceptibility to CC, including the V444A polymorphism, but these associations did not retain statistical significance after Bonferroni correction for multiple testing. Haplotype analysis of the genotyped SNPs in ATP8B1 identified significant differences in frequencies between cases and controls (global p value of 0.005).
CONCLUSION: Haplotypes in ATP8B1 demonstrated a significant difference between CC and control groups. There was a trend towards significant association of V444A with CC. Given the biological plausibility of polymorphisms in ABCB11 and ATP8B1 as risk modifiers for CC, further study in a validation cohort is required.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691113      PMCID: PMC3696362          DOI: 10.1159/000324688

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  39 in total

1.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

Authors:  S A Khan; B R Davidson; R Goldin; S P Pereira; W M C Rosenberg; S D Taylor-Robinson; A V Thillainayagam; H C Thomas; M R Thursz; H Wasan
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

2.  Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.

Authors:  S D Taylor-Robinson; M B Toledano; S Arora; T J Keegan; S Hargreaves; A Beck; S A Khan; P Elliott; H C Thomas
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

Review 3.  Enterohepatic transport of bile salts and genetics of cholestasis.

Authors:  Christiane Pauli-Magnus; Bruno Stieger; Yvonne Meier; Gerd A Kullak-Ublick; Peter J Meier
Journal:  J Hepatol       Date:  2005-08       Impact factor: 25.083

Review 4.  Photodynamic therapy for cholangiocarcinoma: overview and new developments.

Authors:  Maria-Anna Ortner
Journal:  Curr Opin Gastroenterol       Date:  2009-09       Impact factor: 3.287

Review 5.  BSEP: function and role in progressive familial intrahepatic cholestasis.

Authors:  R Thompson; S Strautnieks
Journal:  Semin Liver Dis       Date:  2001-11       Impact factor: 6.115

6.  Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases.

Authors:  E Jacquemin
Journal:  Semin Liver Dis       Date:  2001-11       Impact factor: 6.115

7.  Dietary exposures to food contaminants across the United States.

Authors:  C P Dougherty; S Henricks Holtz; J C Reinert; L Panyacosit; D A Axelrad; T J Woodruff
Journal:  Environ Res       Date:  2000-10       Impact factor: 6.498

8.  Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1-386C>G) in extrahepatic cholangiocarcinoma.

Authors:  Christian Dominik Fingas; Antonios Katsounas; Alisan Kahraman; Winfried Siffert; Christoph Jochum; Guido Gerken; Holger Nückel; Ali Canbay
Journal:  Cancer Invest       Date:  2010-06       Impact factor: 2.176

9.  Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer.

Authors:  A Hoblinger; F Grunhage; T Sauerbruch; F Lammert
Journal:  Digestion       Date:  2009-05-19       Impact factor: 3.216

10.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China.

Authors:  Lian-Yuan Tao; Xiao-Dong He; Qiang Qu; Lei Cai; Wei Liu; Li Zhou; Shang-Ming Zhang
Journal:  Liver Int       Date:  2009-10-14       Impact factor: 5.828

View more
  12 in total

1.  Upregulated expression of Mina53 in cholangiocarcinoma and its clinical significance.

Authors:  Xiao-Ping Tan; Qing Zhang; Wei-Guo Dong; Xia-Wen Lei; Zi-Rong Yang
Journal:  Oncol Lett       Date:  2012-02-28       Impact factor: 2.967

2.  A Case Report of CHEK2 and MUTYH Germline Mutations Associated With Cholangiocarcinoma in a Young Patient.

Authors:  Obaid Rehman; Bradley Sackfield; Viveksandeep Thoguluva Chandrasekar; Jorge Oliver; Ganesh Aswath
Journal:  Cureus       Date:  2022-02-26

3.  Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations.

Authors:  Nimzing G Ladep; Shahid A Khan; Mary Me Crossey; Andrew V Thillainayagam; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

4.  Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort.

Authors:  Munirah Alsaleh; Zoe Leftley; Thomas A Barbera; Larry K Koomson; Abigail Zabron; Mary M E Crossey; Helen L Reeves; Matthew Cramp; Stephen Ryder; Shaun Greer; Martin Prince; Paiboon Sithithaworn; Mohamed Shariff; Narong Khuntikeo; Watcharin Loilome; Puangrat Yongvanit; Yi-Liang Shen; I Jane Cox; Roger Williams; Christopher A Wadsworth; Elaine Holmes; Kathryn Nash; Simon D Taylor-Robinson
Journal:  J Clin Exp Hepatol       Date:  2019-06-15

5.  The Roles of MicroRNA-122 Overexpression in Inhibiting Proliferation and Invasion and Stimulating Apoptosis of Human Cholangiocarcinoma Cells.

Authors:  Ning Liu; Fan Jiang; Tian-Lin He; Jun-Kuan Zhang; Juan Zhao; Chun Wang; Gui-Xing Jiang; Li-Ping Cao; Peng-Cheng Kang; Xiang-Yu Zhong; Tian-Yu Lin; Yun-Fu Cui
Journal:  Sci Rep       Date:  2015-12-21       Impact factor: 4.379

Review 6.  Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges.

Authors:  Fuliang Qian; Junping Guo; Zhi Jiang; Bairong Shen
Journal:  Int J Biol Sci       Date:  2018-05-22       Impact factor: 6.580

7.  Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease.

Authors:  Ragam Attinkara; Jessica Mwinyi; Kaspar Truninger; Jaroslaw Regula; Pawel Gaj; Gerhard Rogler; Gerd A Kullak-Ublick; Jyrki J Eloranta
Journal:  BMC Res Notes       Date:  2012-08-28

8.  Hepatobiliary anomalies associated with ABCB4/MDR3 deficiency in adults: a pictorial essay.

Authors:  Julie Benzimra; Sarah Derhy; Olivier Rosmorduc; Yves Menu; Raoul Poupon; Lionel Arrivé
Journal:  Insights Imaging       Date:  2013-04-17

9.  Atypical presentation of an advanced obstructive biliary cancer without jaundice.

Authors:  Vincent Bryan Salvador; Pushkinder Samrao; Anatoly Leytin; Mohammed Basith
Journal:  Am J Case Rep       Date:  2013-11-06

Review 10.  Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers.

Authors:  Francesca M Trovato; Joshua M Tognarelli; Mary Me Crossey; Daniela Catalano; Simon D Taylor-Robinson; Guglielmo M Trovato
Journal:  World J Hepatol       Date:  2015-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.